In cell culture studies, afatinib was more effective than erlotinib, gefitinib, or lapatinib in inhibiting the survival of lung cancer cell lines harboring wild-type (H1666) or L858R/T790M (NCI-H1975) EGFR, with IC50s (half-maximal inhibitory concentration is drug concentration required for 50% inhibition) below 100 nM, whereas these cells were resistant to the first-generation drugs. Here, EGFR is linked to lung carcinoma.